Cymbalta duloxetine: Extension study data

Data from 181 patients enrolled in an open-label extension of a Phase III trial showed that Cymbalta duloxetine maintained pain reduction for 41 weeks. In 58 patients who initially responded to the compound in the 13-week, placebo-controlled Phase III trial, Cymbalta continued to significantly reduce pain as measured by BPI average pain rating from week 13 to week 54. Cymbalta also showed significant improvements in QOL, RMDQ, CGI-S, BPI-S and BPS-I ratings in the initial responders. There were 18 discontinuations due to adverse events in the extension. Data were presented at the International Association for the Study of Pain conference (EFIC) in Lisbon. ...